Seung Wook Lee

Department of Urology,Hanyang University College of Medicine

• Research is traditionally broken into two categories– Basic and applied research

• Basic research is necessary to further our understanding of normal vs. disease states but does not directly translate this knowledge into clinically useful applications

• Applied research advances the development of new diagnostic tests or drugs for patients based on our understanding of disease development and progression

• The primary goal of translational research– To integrate advancements in molecular biology with

clinical trials, taking research from the “bench-to-bedside”

• The National Institutes of Health (NIH) has made translational research a priority, forming centers of translational research at its institutes and launching the Clinical and Translational Science Award (CTSA) programin 2006

• Besides academic centers, foundations, industry, disease-related organizations, and individual hospitals and health systems have also established translational research programs and at least 2 journals are devoted to the topic

– Translational Medicine

– The Journal of Translational Medicine

• Bench-to-bedside– Enterprise of harnessing knowledge from basic

sciences to produce new drugs, devices, and treatment options for patients

• The interface between basic science and clinical medicine

– The end point is the production of a promising new treatment that can be used clinically or commercialized

• Effective translation of the new knowledge, mechanisms, and techniques generated by advances in basic science research into new approaches for prevention, diagnosis, and treatment of disease is essential for improving health

– The production of a new drug, an end point for “bench-to-bedside” translational research, is only the starting point for this second area of research

• Study of cancer therapy– One prime example of translational research in

human disease• Extensive cooperation between basic researchers, clinicians,

and industry has generated numerous new targeted compounds with enhanced efficacy and decreased toxicity

• Translational research can also be applied to predicting response to therapy and resistance and sensitizing cancer cells to current therapeutics

• Currently, completion of all phases of preclinical and clinical testing of a single drug can take 7-12 years, but the vast amount of translational research being conducted around the world bodes well for more rapid advancements in the near future

Figure 1. Translational research cycle. Laboratory researchers, clinicians, and the pharmaceutical industrymust work together to design rational drugs for improved therapeutic efficacy.

I. 전립선암에서 Gleason's score와 병기에따른 Heat Shock Protein(HSP)27의발현양상에대한연구

1. 세포주에따른 HSP27 유전자발현양상은암세포의악성도에따라증가확인

2. 면역조직화학염색에서도같은경향을확인

→ HSP27의발현은전립선암의악성도와관련

3. doxazosin 처리한 PC-3에서처리농도가높을수록더높은 HSP27의유전자

발현빈도

→ stress와 apoptosis가관련.

II. 전립선암세포주에서 Heat Shock Protein(HSP)27의발현: 전립선암의악성도및 doxazosin처리에따른차이

1. Blocking of of clusterin function with siRNA of HSP27 significantly enhanced doxazosin induced apoptosis in PC-3 cells.

2. Caspase-8 not -9 dependent pathway seems to be involved in this process of doxazosin induced apoptosis in HSP27 silenced PC-3 cells.

III. Doxazosin enhances caspase-dependentapoptotic pathway HSP27 silencing PC-3 cells

보건복지부 보건산업 기술

보건의료기술진흥사업의 목표 및 추진 방향

I. 국가임상시험사업단은 의료산업의 지역 균형 발전과 임상연구 인력개발 및 핵심기술 개발을 위해 정부, 학계, 제약산업계가 뜻을 모아 보건복지가족부 지정 사업단으로 2007년 12월 출범.

II. 국가임상시험사업단은 대한민국의 임상시험 인프라 구축을 위해 지역임상시험센터 지정 및 시설 장비 확충, 임상시험 전문인력 양성, 임상시험 신기술개발을 지원. 또한, 국내외 관련 기관 및 연구자 간의 네트워크를 활성화해 ‘대한민국을 세계적인 임상시험 허브로’ 도약하기 위한 구심점 역할을 수행.

< 국가임상시험사업단 >

Conclusion

1. INTEGRATION of basic & clinical reserach without disruption

2. DIFFERENT THINGS to different people, but important to almost everyone !

3. GENERAL TREND in now and future’s medical study !

4. HUMAN network !

Translational Research ?